Krystal Biotech stock jumps after FDA expands VYJUVEK label
PositiveFinancial Markets

Krystal Biotech's stock surged following the FDA's decision to expand the label for its product VYJUVEK. This expansion is expected to enhance the product's market potential and boost investor confidence.
Editor’s Note: The FDA's approval is a significant milestone for Krystal Biotech, as it not only validates the efficacy of VYJUVEK but also opens new avenues for treatment options. This could lead to increased sales and a stronger position in the biotech market.
— Curated by the World Pulse Now AI Editorial System